JonesResearch downgraded Theratechnologies (THTX) to Hold from Buy after the company announced an agreement with CB Biotechnology, an affiliate of Future Pak, to be acquired for $3.01 per share in cash plus one contingent value right per share for additional aggregate cash payments of up to $1.19 per CVR if certain milestones are achieved.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on THTX: